Dana-Farber Cancer Institute (Main)
Boston, MA
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
MDS Centers of Excellence
Accepting patients
FHD-286
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies
Learn more- BRG1 Inhibitor
- BRM Inhibitor
- Phase 1
- Has results
Accepting patients
SL-172154
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Learn more- Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
DFV890
A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
Learn more- NLRP3 Inhibitor
- Phase 1
Accepting patients
KT-253
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors
Learn more- MDM2 Inhibitor
- Phase 1
Accepting patients
TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- IRAK 4 Inhibitor
- Phase 1/2
- Has results
Accepting patients
BXCL701
A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2
Learn more- Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
- Phase 1
Accepting patients
SL-401
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 1
Accepting patients
AZD6738
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Learn more- Kinase Inhibitor
- Phase 1
Accepting patients
IS-free Treg Stem Cell Transplant
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS
Learn more- Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
Venetoclax in Pre- and Post-Transplant Therapy
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes
Learn more- Allogeneic Stem Cell Transplant
- Antimetabolites
- BCL-2 Inhibitor
- Chemotherapy
- Hypomethylating Agents (HMA)
- Phase 1